

Detection and Evaluation of Chronic Kidney Disease

SUSAN SNYDER, M.D., and BERNADETTE PENDERGRAPH, M.D.
Harbor-University of California, Los Angeles Medical Center, Torrance, California

Chronic kidney disease affects approximately 19 million adult Americans, and its incidence is increasing rapidly. Diabetes and hypertension are the underlying causes in most cases of chronic kidney disease. Evidence suggests that progression to kidney failure can be delayed or prevented by controlling blood sugar levels and blood pressure and by treating proteinuria. Unfortunately, chronic kidney disease often is overlooked in its earliest, most treatable stages. Guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) recommend estimating glomerular filtration rate and screening for albuminuria in patients with risk factors for chronic kidney disease, including diabetes, hypertension, systemic illnesses, age greater than 60 years, and family history of chronic kidney disease. The glomerular filtration rate, calculated by using a prediction equation, detects chronic kidney disease more accurately than does the serum creatinine level alone; the glomerular filtration rate also is used for disease staging. In most clinical situations, analysis of random urine samples to determine the albumin-creatinine or protein-creatinine ratio has replaced analysis of timed urine collections. When chronic kidney disease is detected, an attempt should be made to identify and treat the specific underlying condition(s). The KDOQI guidelines define major treatment goals for all patients with chronic kidney disease. These goals include slowing disease progression, detecting and treating complications, and managing cardiovascular risk factors. Primary care physicians have an important role in detecting chronic kidney disease early, in instituting measures to slow disease progression, and in providing timely referral to a nephrologist. (*Am Fam Physician* 2005;72:1723-32, 1733-4. Copyright © 2005 American Academy of Family Physicians.)

► **Patient information:**
A handout on chronic kidney disease, written by the authors of this article, is provided on page 1733.

Approximately 19 million Americans older than 20 years have chronic kidney disease, and an additional 435,000 have end-stage renal disease (*Table 1*¹). The incidence of end-stage renal disease, with its annual mortality rate of 24 percent, has doubled every decade since 1980.² Chronic kidney disease is 100 times more prevalent than end-stage renal disease, and its incidence is increasing at an even faster rate.

Early treatment of chronic kidney disease and its complications may delay or prevent the development of end-stage renal disease. Consequently, detection of chronic kidney disease should be a priority for family physicians. However, data from national screening programs suggest that chronic kidney disease often is not detected, even when patients have access to primary care.^{3,4}

The Kidney Disease Outcomes Quality Initiative (KDOQI) from the National Kidney Foundation (NKF) has developed guidelines for the detection and evaluation of chronic kidney disease.^{5,6} These guidelines define the disease and its stages and outline

treatment goals for each stage. This article focuses on the detection of chronic kidney disease and the initial evaluation of affected patients.

Detection of Chronic Kidney Disease WHICH PATIENTS TO SCREEN

The KDOQI guidelines^{1,6} recommend assessing all patients for kidney-disease risk factors. Further screening is performed in patients with identified risk factors. Although screening methods for chronic kidney disease have not been evaluated in randomized controlled trials,⁷ the high prevalence of the disease in at-risk populations, the ease of screening, and the availability of effective treatments during early asymptomatic stages of the disease provide sufficient rationale for screening.⁸ Nonetheless, screening rates for patients with known risk factors for chronic kidney disease are as low as 20 percent.^{3,4}

High-risk groups that should be screened for chronic kidney disease include patients who have a family history of the disease and patients who have diabetes, hypertension, recurrent urinary tract infections,

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
All adults with risk factors for chronic kidney disease should be screened with a serum creatinine determination for GFR estimation and analysis of a random urine sample for proteinuria.	C	1, 5, 6
Instead of a timed urine collection, a random urine sample for the microalbumin-creatinine or protein-creatinine ratio should be used to quantify proteinuria.	C	1, 24, 25
Interventions proved to slow the progression of chronic kidney disease include blood pressure control, glycemic control, and reduction of proteinuria with an angiotensin-converting enzyme inhibitor or angiotensin-II receptor blocker.	A	1, 24, 33, 34, 37
A low-density lipoprotein goal of less than 100 mg per dL (2.60 mmol per L) is recommended for patients with chronic kidney disease, because these patients are statistically at highest risk for cardiovascular disease.	C	37
A blood pressure goal of 130/80 mm Hg is recommended in patients with normal urinary albumin concentrations, and a blood pressure goal of 125/75 mm Hg is recommended in patients with proteinuria equal to or greater than 1 g per 24 hours.	B	1, 30

GFR = glomerular filtration rate.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 1639 or <http://www.aafp.org/afpsort.xml>.

urinary obstruction, or a systemic illness that affects the kidneys.¹ A recent analysis⁹ suggested that screening all patients older than 60 years is cost-effective even when other risk factors for chronic kidney disease are absent; screening low-risk patients younger than 60 years does not appear to be cost-effective.

Diabetes is the most common cause of kidney disease. From 40 to 60 percent of patients who progress to end-stage renal disease have diabetes. Other underlying conditions in patients with end-stage renal disease include hypertension (15 to 30 percent),

glomerulonephritis (less than 10 percent), and cystic kidney (2 to 3 percent). Unknown causes account for the remaining patients with end-stage renal disease.²

HOW TO SCREEN

Screening patients at risk for chronic kidney disease relies on the detection of functional abnormalities using readily available, inexpensive laboratory tests. The measured serum creatinine level is used to calculate an estimated glomerular filtration rate (GFR). Screening for proteinuria often alerts the physician to the presence of chronic kidney disease before changes in the GFR become apparent.

Current KDOQI guidelines^{1,5,6} recommend screening for kidney disease with a serum creatinine measurement for use in GFR estimation and analysis of a random urine sample for albuminuria. Significant kidney disease can present with decreased GFR or proteinuria, or both. An analysis⁷ of data from the third National Health and Nutrition Examination Survey (NHANES III) showed that 20 percent of persons with diabetes, and 43 percent of persons with hypertension and a GFR below 30 mL per minute per 1.73 m², had no proteinuria. Therefore, an estimate of the GFR and a screening method for proteinuria are required.¹

Selected patients with risk factors for kidney disease should be screened with renal ultrasonography. Indications for this study

TABLE 1
Definitions from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative

Chronic kidney disease

Kidney damage for three or more months based on findings of abnormal structure (imaging studies) or abnormal function (blood tests, urinalysis)
or
GFR below 60 mL per minute per 1.73 m² for three or more months with or without evidence of kidney damage

End-stage renal disease (kidney failure)

GFR below 15 mL per minute per 1.73 m²
or
Need for kidney replacement therapy (dialysis or transplant)

GFR = glomerular filtration rate.

Adapted with permission from National Kidney Foundation. K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 suppl 1):S1-266. Accessed online February 15, 2005, at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/GIF_File/kck_t2.gif.

TABLE 2

Stages of Chronic Kidney Disease Based on Estimated GFR

Stage	GFR (mL per minute per 1.73 m ²)
1	≥90
2	60 to 89
3	30 to 59
4	15 to 29
5	<15 or dialysis

GFR = glomerular filtration rate.

Information from reference 1.

include suspected urinary tract obstruction, recurrent urinary tract infections, vesico-ureteral reflux, and a family history of polycystic kidney disease.¹

ESTIMATING THE GFR

The GFR is an indication of functioning kidney mass; it has implications for treatment goals and for the dosing of renally excreted medications.¹⁰ The KDOQI guidelines define stages of chronic kidney disease based on an estimated GFR that is calculated from the serum creatinine level (*Table 2*¹).

The standard for GFR measurement is the clearance rate of inulin, a substance that passes through the kidney unchanged. Creatinine clearance, as measured by a 24-hour urine collection, usually overestimates the GFR because of the active secretion of creatinine by the kidney and can vary with muscle mass.¹¹

Significant kidney dysfunction may be present despite a normal serum creatinine level. An estimation of the GFR based on the serum creatinine level correlates better with direct measures of the GFR and detects more cases of chronic kidney disease than does the serum creatinine level alone. Furthermore, patients with the same serum creatinine level may have different estimated GFRs. For example, a 45-year-old black man whose serum creatinine level is 1 mg per dL (88 μmol per L) has normal kidney function with an estimated GFR of 130 mL per minute per 1.73 m², whereas a 65-year-old white woman with the same serum creatinine level has an estimated GFR of 59 mL per minute per 1.73 m², or stage 3 kidney disease.

Based on an analysis⁷ of NHANES III data, 20 percent of persons with diabetes, and

14.2 percent of persons with hypertension but no diabetes, have a GFR below 60 mL per minute per 1.73 m². The prevalence of GFRs below 60 mL per minute per 1.73 m² increases steadily with age; 22.5 percent of nondiabetic, nonhypertensive octogenarians have a GFR below this level.

Clinically useful GFR estimates are calculated from the measured serum creatinine level^{12,13} after adjustments for age, sex, and race. A GFR of 100 mL per minute per 1.73 m² is considered normal for women, and 120 mL per minute per 1.73 m² is a normal GFR for men.¹ The two most commonly used formulas for GFR estimation are shown in *Table 3*.¹²⁻¹⁸ These methods have been studied in a variety of populations.^{12,14-18} Validation studies¹² performed in middle-aged patients with chronic kidney disease showed that the Modification of Diet in Renal Disease (MDRD) study equation was more accurate than the Cockcroft-Gault equation, which calculates creatinine clearance. In a recent study,¹⁸ however, the MDRD study equation was found to systematically underestimate the GFR in patients without chronic kidney disease.

In most situations and as long as kidney function is stable, a calculated GFR can replace measurement of a 24-hour urine collection for creatinine clearance. A user-

TABLE 3

Formulas for Estimating GFR in Adults***Abbreviated MDRD study equation^{12†}**

$$\text{GFR (mL per minute per 1.73 m}^2\text{)} = 186 \times (S_{Cr})^{-1.154} \times (\text{age})^{-0.203} \\ \times (0.742, \text{ if female}) \times (1.210, \text{ if black})$$

Cockcroft-Gault equation¹³

$$C_{Cr} \text{ (mL per minute)} = \frac{(140 - \text{age}) \times \text{weight}}{72 \times S_{Cr}} \times (0.85, \text{ if female})$$

GFR = glomerular filtration rate; MDRD = Modification of Diet in Renal Disease; S_{Cr} = serum creatinine concentration; C_{Cr} = creatinine clearance.

*—For each equation, S_{Cr} is in milligrams per deciliter, age is in years, and weight is in kilograms.

†—In validation studies,¹⁴⁻¹⁷ the MDRD study equation performed as well as versions with more variables; however, a recent study¹⁸ found that the equation underestimated the GFR in patients who did not have chronic kidney disease.

Information from references 12 through 18.

TABLE 4

Preferred Methods for Assessing Kidney Function

<i>Method</i>	<i>Situations for use</i>
MDRD study equation for estimating GFR*	Patients with diabetic kidney disease† Patients with chronic kidney disease in middle-age (average age: 51 years)† Black patients with hypertensive chronic kidney disease† Patients with a kidney transplant†
Cockcroft-Gault equation for estimating creatinine clearance*	Older patients (performs better than the MDRD study equation)
24-hour urine collection for creatinine clearance	Pregnant women Patients with extremes of age and weight Patients with malnutrition Patients with skeletal muscle diseases Patients with paraplegia or quadriplegia Patients with a vegetarian diet and rapidly changing kidney function

MDRD = Modification of Diet in Renal Disease; GFR = glomerular filtration rate.

*—Requires stable kidney function.

†—Validated for use in these patients.

Based on information from references 3 and 12 through 17.

friendly GFR calculator is available online at http://www.kidney.org/professionals/kdoqi/gfr_page.cfm. Determination of creatinine clearance using a 24-hour urine collection is still required to assess kidney function in patients with the conditions listed in *Table 4*.^{3,12-17}

DETECTING AND QUANTITATING PROTEINURIA

Proteinuria is associated with more rapid progression of chronic kidney disease and a greater likelihood of developing end-stage renal disease. Consequently, detection and quantitation of proteinuria are essential to the diagnosis and treatment of chronic kidney disease.

Reducing proteinuria with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-II receptor blocker (ARB) slows the progression of chronic kidney disease in patients with or without diabetes.^{19,20} Quantitative measures of proteinuria also are used to monitor response to therapy.

Albumin, the predominant protein excreted by the kidney in most types of renal disease, is detected readily by urine dipstick testing. In some condi-

tions, immunoglobulins also may be excreted in urine. The protein-creatinine ratio in an early-morning random urine sample correlates well with 24-hour urine protein excretion and is much easier to obtain.¹

An analysis⁷ of NHANES III data showed that 8.3 percent of 14,622 adults had microalbuminuria (i.e., excretion of 30 to 300 mg of albumin per 24 hours) and 1 percent had macroalbuminuria (i.e., excretion of more than 300 mg of albumin per 24 hours). Albuminuria was detected in one of every three persons with diabetes, one of every seven persons with hypertension but no diabetes, and one of every six persons older than 60 years.

Microalbuminuria often heralds the onset of diabetic nephropathy. In a recent study²¹ of patients with type 1 diabetes, spontaneous regression of microalbuminuria occurred in some patients, suggesting that microalbuminuria may represent an initial reversible phase of kidney damage rather than the beginning of an inexorable progression to end-stage renal disease.²²

The KDOQI guidelines¹ and the American Diabetes Association (ADA) guidelines²³ recommend screening for microalbuminuria in all patients at risk for kidney disease. Screening can be performed using a microalbumin-sensitive dipstick or analysis of a random morning urine sample to determine the microalbumin-creatinine ratio. Microalbumin dipsticks have a sensitivity of 51 to 100 percent and a specificity of 27 to 97 percent.²⁴ The ADA²⁵ recommends repeated sampling, but the NKF¹ and others question the necessity for this. An algorithm for detecting proteinuria and microalbuminuria is provided in *Figure 1*.¹

The value of screening for microalbuminuria has been questioned in patients who already are receiving ACE-inhibitor therapy²⁶ on the basis that the results are unlikely to change management. One study²⁷ in patients with type 2 diabetes showed that increasing the dose of an ARB to decrease or eliminate microalbuminuria provides additional benefit in slowing progression to overt nephropathy. Therefore, current research suggests that it may be beneficial to monitor patients with

Proteinuria is associated with more rapid progression of chronic kidney disease and a greater likelihood of developing end-stage renal disease.

Evaluation for Proteinuria and Microalbuminuria




Figure 1. Algorithm for proteinuria and microalbuminuria screening in the patient with risk factors for chronic kidney disease.

Adapted with permission from National Kidney Foundation. *K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.* *Am J Kidney Dis* 2002;39(2 suppl 1):S1-266. Accessed online February 21, 2005, at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/Gif_File/kck_f57.gif.

chronic kidney disease, including those who are taking an ACE inhibitor or ARB, for persistence of microalbuminuria or for progression to overt proteinuria. The medication dosage should be adjusted as tolerated, with the goal of eliminating albuminuria.

Evaluation of Patients with Chronic Kidney Disease

Once chronic kidney disease has been identified, goals include determining the stage of the disease, establishing the cause of the disease, and evaluating comorbid conditions. All patients with chronic kidney disease should undergo urinalysis and renal imaging as part of the diagnostic evaluation. Patients with long-standing diabetes, hypertension, and a clinical course consistent with chronic kidney disease secondary to these conditions may not require further evaluation.¹

The evaluation of all patients is guided by the symptoms (e.g., rash, arthritis, or urinary symptoms); family history of kidney disor-

ders (e.g., cystic kidney diseases); and known medical problems. Underlying diseases may be identified by the physical examination, with special attention given to the skin, joints, and cardiovascular system. *Table 5*²⁸ summarizes the common presentations and appropriate serologic evaluations for the most common causes of chronic kidney disease.

Several tests may help determine the underlying cause of chronic kidney disease. Tests for complements 3 and 4 are used to screen for collagen vascular disease, hepatitis C-related disease, and infection-related immune complex disease. The antineutrophil cytoplasmic antibody assay identifies vasculitis, whereas serum protein electrophoresis and urine protein electrophoresis detect multiple myeloma.

Renal ultrasonography helps establish the diagnosis and prognosis by documenting the size of the kidneys. Normal size indicates kidney disease that may be amenable to medical treatment. Small kidneys suggest

TABLE 5

Diagnostic Evaluation in Chronic Kidney Disease

<i>Disorder</i>	<i>Clinical clues</i>	<i>Urine sediment</i>	<i>Protein-creatinine ratio</i>	<i>Additional tests</i>
Diabetes mellitus	Diabetes for > 15 years, retinopathy	RBCs in <25 percent of affected patients	>30 to >3,500 mg of protein per g of creatinine	Fasting blood sugar, A1C
Essential hypertension	Left ventricular hypertrophy, retinopathy	Benign	>30 to 3,000 mg of protein per gram of creatinine	No additional tests
Glomerulonephritis	History and physical examination: infections; rash, arthritis; patient older than 40 years	Dysmorphic RBCs or RBC casts	>30 to >3,500 mg of protein per g of creatinine	C3 and C4 for all patients Tests for infections: anti-ASO, ASK, HIV, HBsAg, HCV, RPR, blood cultures Tests if there is rash or arthritis: ANA, ANCA, cryoglobulin, anti-GBM Tests if patient is older than 40 years: SPEP, UPEP
Interstitial nephritis	Medications, fever, rash, eosinophilia	WBCs, WBC casts, eosinophils	30 to 3,000 mg of protein per g of creatinine	ACE level; SS-A, SS-B
Low flow states	Volume depletion, hypotension, congestive heart failure, cirrhosis, atherosclerosis	Hyaline casts, eosinophils	<200 mg of protein per g of creatinine	FENa: <1 percent; eosinophilia
Urinary tract obstruction	Urinary symptoms	Benign, or RBCs	None	KUB radiography, intravenous pyelography, spiral CT scanning, renal ultrasonography
Chronic urinary tract infection	Urinary symptoms	WBCs, RBCs	<2,000 mg of protein per g of creatinine	Pelvic examination, urine culture, voiding cystourethrography, renal ultrasonography, CT scanning
Neoplasm, paraproteinemia	Patient older than 40 years, constitutional symptoms, anemia	RBCs, RBC casts, granular casts	False-negative result or >30 to >3,500 mg of protein per g of creatinine	SPEP, UPEP, calcium level, ESR
Cystic kidney disease	Palpable kidneys with or without family history of cystic kidney disease, flank pain	RBCs	30 to 3,000 mg of protein per g of creatinine	Renal ultrasonography or CT scanning if there is a complex kidney cyst or mass
Renovascular disease	Late-onset or refractory hypertension, sudden onset of hypertension in young woman, smoking history, abdominal bruit	Benign	<200 mg of protein per g of creatinine	Renal Doppler ultrasonography, radioisotope renal scanning, MRA, renal angiography
Vasculitis	Constitutional symptoms, peripheral neuropathy, rash, respiratory symptoms	RBCs; granular casts	>30 to >3,500 mg of protein per g of creatinine	C3, C4, ANA, ANCA; HBsAg, HCV, cryoglobulins, ESR, RF, SS-A, SS-B, HIV

RBC = red blood cell; A1C = glycosylated hemoglobin; C3 = complement 3; C4 = complement 4; anti-ASO = streptolysin O latex antibody; ASK = antistreptokinase; HIV = human immunodeficiency virus; HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; RPR = rapid plasma reagin; ANA = antinuclear antibodies; ANCA = antineutrophil cytoplasmic antibody; anti-GBM = anti-glomerular basement membrane antibody; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; WBC = white blood cell; ACE = angiotensin-converting enzyme; SS-A = anti-Ro antibody; SS-B = anti-La antibody; FENa = fractional excretion of sodium; KUB = kidney, ureters, and bladder; CT = computed tomography; ESR = erythrocyte sedimentation rate; MRA = magnetic resonance angiography; RF = rheumatoid factor.

Adapted from *Chronic kidney disease and pre-ESRD. Management in the primary care setting*. Accessed February 24, 2005, at: http://www.oqp.med.va.gov/cpg/ESRD/ESRD_cpg/app/bot_app_1.htm.

irreversible disease. Asymmetry in kidney size suggests renovascular disease.

Imaging studies that may be useful in identifying the cause of chronic kidney disease are listed in *Table 6*.^{1,28} Renal biopsy is indicated when the cause cannot be determined by the history and laboratory evaluation, when the patient's signs and symptoms suggest parenchymal disease, and when the differential diagnosis includes diseases that require different treatments or that have different prognoses.¹¹ Biopsy more commonly is required in patients with chronic kidney disease that is not related to diabetes, and biopsy often is indicated in adult patients with nephrotic syndrome or suspected glomerulonephritis. Based on an international survey²⁹ of nephrologists, rates of biopsy vary widely in practice.

The management of chronic kidney disease depends on the specific treatment of the underlying cause, the stage of the kidney disease, and the presence or absence of proteinuria. Treatment goals for all patients include slowing disease progression, detecting and managing complications, and preventing cardiovascular disease.

RATE OF DISEASE PROGRESSION

The rate of progression for chronic kidney disease depends on the underlying cause. In general, tubulointerstitial diseases progress more slowly than do glomerular diseases, diabetic and hypertensive nephropathy, and polycystic kidney disease.¹¹ Rates of progression also vary widely among patients with the same type of kidney disease.

In rapidly progressing kidney disease, the GFR may decrease by as much as 10 to 20 mL per minute per 1.73 m² per year. In more slowly progressing disease, the GFR may decrease by as little as 2 mL per minute per 1.73 m² per year. Plotting the GFR against time is helpful in estimating the rate of disease progression and the time to kidney failure, and it helps predict the need for kidney replacement therapy (*Figure 2*¹).

Three interventions have been proved to slow the progression of kidney disease: blood pressure control,³⁰ glycemic control in patients with diabetes,¹ and reduction of proteinuria with an ACE inhibitor or

TABLE 6

Imaging Options in Chronic Kidney Disease

<i>Imaging study</i>	<i>What the study helps identify</i>
Plain-film radiography of kidneys, ureters, and bladder	Ureter or bladder stones
Renal ultrasonography	Kidney size, obstructive kidney disease, polycystic kidney disease
Renal Doppler ultrasonography	Renovascular disease, renal vein thrombosis
Radioisotope renal scanning	Individual kidney function, renovascular disease, obstructive uropathy
Computed tomography	Kidney mass or complex cyst
Magnetic resonance angiography	Renovascular disease
Renal angiography	Renovascular disease, renal artery thrombosis/thromboembolism, polyarteritis nodosa
Retrograde ureterography	Upper urinary tract obstruction

NOTE: Intravenous pyelography generally is not performed in patients with chronic kidney disease because it may precipitate acute renal failure.

Information from references 1 and 28.

ARB.^{19,20,31,32} Other interventions that may be beneficial include lipid-lowering measures, partial correction of anemia,¹ and limiting dietary protein intake to 0.60 to 0.75 g per kg of body weight per day in patients with a GFR below 25 mL per minute per 1.73 m².³³

COMPLICATIONS

Complications of chronic kidney disease affect every organ system. Patients with a GFR below 60 mL per minute per 1.73 m² should undergo periodic monitoring for the complications listed in *Table 7*.^{1,28}

Clinical evaluation may detect gastrointestinal, neurologic, dermatologic, and musculoskeletal complications in the advanced stages of chronic kidney disease. Gastrointestinal symptoms may herald the onset of uremia, indicating the need for kidney replacement therapy.

Laboratory tests detect complications such as electrolyte abnormalities, disordered calcium or phosphorus metabolism, and anemia. Patients with nephrotic-range proteinuria are at risk for hypoalbuminemia and immune dysfunction because of the loss of immunoglobulins. Periodic monitoring of the total serum protein level and the albumin level is indicated in these patients. Nutritional status should be evaluated because malnutrition adversely affects prognosis.

Estimating the Time to Kidney Failure




Figure 2. Estimating the progression of chronic kidney disease. A plot of the glomerular filtration rate (GFR) over time can be used to predict the time to end-stage renal disease.

Information from reference 1.

RISK OF CARDIOVASCULAR DISEASE

Cardiovascular disease is the most common cause of death in patients with chronic kidney disease. The risk of cardiovascular disease and associated mortality increases in proportion to the decrease in the GFR.³⁴ Patients with albuminuria and normal GFR also are at increased risk. Evaluation for traditional cardiovascular risk factors, including smoking, high lipid levels, hypertension, and sedentary lifestyle, is essential. The KDOQI guidelines¹ recommend a blood pressure goal of 130/80 mm Hg in patients with normal urinary albumin concentrations, and a blood pressure goal of 125/75 mm Hg in patients

with excretion of more than 1 g of protein per 24 hours. A long-term follow-up study³⁵ of patients with nondiabetic kidney disease and an average GFR of 32 mL per minute per 1.73 m² found that the patients randomized to a low blood pressure target were one third less likely to develop kidney failure than were the patients randomized to a usual blood pressure goal.

The KDOQI guidelines on managing dyslipidemias³⁶ in chronic kidney disease recommend a low-density lipoprotein cholesterol goal of less than 100 mg per dL (2.60 mmol per L) for patients with chronic kidney disease, because they are statistically at highest risk for cardiovascular disease. In these patients, the 10-year risk for mortality from cardiovascular disease exceeds 20 percent.³⁶

Paradoxically, dialysis patients with the lowest cholesterol levels are the most likely to die of cardiovascular disease. This is because low levels of cholesterol are associated with nontraditional cardiac risk factors of malnutrition and are markers of chronic inflammation.³⁷ Lipid disorders should be treated aggressively in patients with chronic kidney disease and end-stage renal disease.³⁶

Additional cardiac risk factors specific to chronic kidney disease include volume overload, hyperparathyroidism, and uremia. Anemia caused by decreased erythropoietin production also may contribute to cardiovascular mortality. Treatment with exogenous

The Authors

SUSAN SNYDER, M.D., is associate clinical professor of family medicine in the Department of Family Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). She also is vice chair for academic affairs for the Department of Family Medicine and director of the primary care faculty development fellowship at Harbor-UCLA Medical Center, Torrance, Calif. Dr. Snyder received her medical degree from the University of Vermont College of Medicine, Burlington, and completed a family medicine residency at San Francisco General Hospital.

BERNADETTE PENDERGRAPH, M.D., is a faculty member in the family medicine residency program at Harbor-UCLA Medical Center and serves as assistant director of the primary care sports medicine fellowship. Dr. Pendergraph earned her medical degree at the David Geffen School of Medicine at UCLA. She completed a surgical internship, family medicine residency, faculty development fellowship, and sports medicine fellowship at Harbor-UCLA Medical Center.

Address correspondence to Susan Snyder, M.D., Harbor-UCLA Medical Center, 1403 W. Lomita Blvd., Suite 102, Harbor City, CA 90710 (e-mail: ssnyder@labiomed.org). Reprints are not available from the authors.

erythropoietin has been shown to improve the prognosis.³⁸

WHEN TO REFER

Nephrology referral generally is recommended for patients with a serum creatinine level of 1.5 to 2.0 mg per dL (133 to 177 μ mol per L). According to one estimate, that would mean seven new patients per day for every nephrologist in the United States.³⁹ Some indications for nephrology referral are listed in Table 8.^{6,11,28,38,40}

The value of timely referral has been demonstrated,⁴⁰ but the contribution of primary care to outcomes in patients with chronic kidney disease has not been studied.⁴¹ Given the magnitude of the rapid increase in the number of cases of chronic kidney disease, primary care evaluation and timely referral are recommended. The KDOQI endorses a model of collaboration between primary care physicians and subspecialists.⁶ The National Kidney Disease Education Program provides tools to promote this collaboration; they may be accessed online at <http://www.nkdep.nih.gov/professionals/index>.

Author disclosure: Nothing to disclose.

REFERENCES

1. National Kidney Foundation. K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39 (2 suppl 1):S1-266. Accessed online February 15, 2005, at: http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm.
2. United States renal data survey. Annual data report, 2003. Accessed online February 15, 2005, at: http://www.usrds.org/adr_2003.htm.
3. National Kidney Foundation. KEEP: Kidney Early Evaluation Program. Annual data report. Program introduction. *Am J Kidney Dis* 2003;42(5 suppl 4):S5-15. Accessed online February 15, 2005, at: http://www.kidney.org/keep/pdf/ajkd_KEEP_nov_2003.pdf.
4. McClellan WM, Ramirez SP, Jurkovic C. Screening for chronic kidney disease: unresolved issues. *J Am Soc Nephrol* 2003;14(7 suppl 2):S81-7.
5. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. *Semin Nephrol* 2002;22:449-58.
6. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med* 2003;139:137-47.
7. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides

TABLE 7

Screening for Complications in Chronic Kidney Disease (Stages 3 and 4*)

Test	Complications detected
Hemoglobin concentration	Anemia
Red blood cell indexes, reticulocyte count, iron studies, fecal occult blood test	For ruling out other causes of anemia before erythropoietin therapy is started
Serum electrolyte levels	Hyperkalemia, hyponatremia, acidosis
Calcium, phosphorus, and parathyroid hormone levels	Hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism
Serum albumin and total protein levels	Hypoalbuminemia, decreased levels of immunoglobulins in patients with nephritic levels of proteinuria or signs of malnutrition

*—Patients with a glomerular filtration rate below 60 mL per minute per 1.73 m². Information from references 1 and 28.

TABLE 8

Indications for Nephrology Referral in Chronic Kidney Disease

- Underlying cause unclear after basic work-up
- Renal biopsy indicated
- Management of underlying cause beyond the scope of primary care
- Stage 3 chronic kidney disease (GFR <60 mL per minute per 1.73 m²): consider comanagement
- Stage 4 chronic kidney disease (GFR <30 mL per minute per 1.73 m²): nephrologist involvement essential
- Rapid progression of chronic kidney disease
- Superimposed acute kidney failure

GFR = glomerular filtration rate.

Information from references 6, 11, 28, 38, and 40.

- population screening: results from the NHANES III. *Kidney Int* 2002;61:2165-75.
- 8. Barratt A, Irwig L, Glasziou P, Cumming RG, Raffle A, Hicks N, et al. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group. *JAMA* 1999;281:2029-34.
- 9. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. *JAMA* 2003;290:3101-14.
- 10. National Kidney Foundation. Kidney learning system. CKD clinical action plan. Accessed online March 9, 2005, at: <http://www.kidney.org/kls/professionals/cap.cfm>.
- 11. Greenberg A, Cheung AK, National Kidney Foundation. Primer on kidney diseases. 3d ed. San Diego: Academic Press, 2001.
- 12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461-70.

13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.
14. Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, et al. Comparison of cross-sectional measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. *Am J Kidney Dis* 2001;38:744-53.
15. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. *Nephrol Dial Transplant* 2002;17:1909-13.
16. Beddhu S, Samore MH, Robert MS, Stoddard GJ, Pappas LM, Cheung AK. Creatinine production, nutrition, and glomerular filtration rate estimation. *J Am Soc Nephrol* 2003;14:1000-5.
17. Lamb EJ, Webb MC, Simpson DE, Coakley AJ, Newman DJ, O'Riordan SE. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement? *J Am Geriatr Soc* 2003;51:1012-7.
18. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Ann Intern Med* 2004;141:929-37.
19. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 2003;139:244-52.
20. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE substudy. *Lancet* 2000;355:253-9.
21. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. *N Engl J Med* 2003;348:2285-93.
22. Winocour PH, Marshall SM. *Microalbuminuria: biochemistry, epidemiology, and clinical practice*. New York: Cambridge University Press, 1998.
23. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. American Diabetes Association. Nephropathy in diabetes. *Diabetes Care* 2004;29(suppl 1):S79-83.
24. National electronic Library for Health. Clinical guidelines for type 2 diabetes: renal disease-prevention and early management, part 6: screening tests for renal disease in type 2 diabetes. Accessed online February 16, 2005, at: <http://www.nelh.nhs.uk/guidelinesdb/html/fulltext-guidelines/rcgprenal-6.html>.
25. Scheid DC, McCarthy LH, Lawler FH, Hamm RM, Reilly KE. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. *J Fam Pract* 2001;50:661-8.
26. Hale WA, Nashelsky J, Wilson SA. Clinical inquiries. Does screening for microalbuminuria in diabetes prevent complications? *J Fam Pract* 2003;52:229-31.
27. Parving HH, Lehnert N, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001;345:870-8.
28. Chronic kidney disease and pre-ESRD. Management in the primary care setting. Accessed February 24, 2005, at: http://www.oqp.med.va.gov/cpg/ESRD/ESRD_cpg/frameset.htm.
29. Fuiano G, Mancuso D, Comi N, Mazza G, Fabiano G. Renal biopsy: clinical indications. In: 2nd International Congress of Nephrology in Internet. 2001. Accessed online March 25, 2005, at: <http://www.uninet.edu/cin2001/html/conf/fuiano.html>.
30. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* 1995;123:754-62.
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-9.
32. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient level data [published correction appears in *Ann Intern Med* 2002;137:299]. *Ann Intern Med* 2001;135:73-87.
33. Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. *Kidney Int* 1997;52:778-91.
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004;351:1296-305.
35. Sarnak MJ, Green T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. *Ann Intern Med* 2005;142:342-51.
36. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease, part 3, guideline 4. Accessed online February 16, 2005, at: http://www.kidney.org/professionals/kdoqi/guidelines_lipids/iii.htm.
37. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink ME, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. *JAMA* 2004;291:451-9.
38. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000 [published correction appears in *Am J Kidney Dis* 2001;38:442]. *Am J Kidney Dis* 2001;37(1 suppl 1):S182-238.
39. United States Department of Health and Human Services, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Chronic kidney disease in the United States. Accessed online February 16, 2005, at: http://www.nkdep.nih.gov/educresources/nkdep_cdk_presentation.pdf.
40. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag M, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. *Ann Intern Med* 2002;137:479-86.
41. Levinsky NG. Specialist evaluation in chronic kidney disease: too little, too late. *Ann Intern Med* 2002;137:542-3.